In a market where transparency is now a legal mandate rather than a marketing buzzword, how do you distinguish between PBMs that are merely complying on paper and those that are truly innovating and aligning with clients? It starts with a deep understanding of the newest passed (and proposed) legislation and modern PBM models that are already one step ahead.

Join SmithRx’s Chief Strategy Officer, Alan Pannier, for an executive analysis of the most recent federal legislation and regulations, the rise of direct-to-consumer (DTC) platforms, what they mean for your plan spend, and the insights your plan needs to thrive in a “post-rebate” era.

In this episode, we’ll explore:

• Why CAA 2026 makes pharmacy benefits oversight your fiduciary responsibility

• How direct-to-consumer portals can be a helpful fact-checking mechanism

• Which PBM models will thrive in a “no-middleman” benefits future